Please login to view this media
- Talk
- 22/09/2021
- UK
Evaluating the Role of Carbon Fibre Reinforced Polyetheretherketone and Titanium Intramedullary Nails in Patients with Metastatic Bone Disease
Description
The presentation delivered by Ash Ahluwalia at a UCL rotation discusses a retrospective cohort study comparing the effectiveness of carbon-fiber PEEK nails versus titanium nails in patients with metastatic bone disease. Ash begins by highlighting potential theoretical advantages of carbon-fiber nails, like their closer modulus of elasticity to cortical bone, improved fatigue resistance, and better compatibility with MRI and CT imaging. He points out the significant cost difference, with carbon-fiber nails being approximately £1,000 more expensive than titanium alternatives.
Data were collected over five years to assess two primary groups requiring intramedullary nailing: those receiving prophylactic nails and those being treated for fractures. The study aimed to evaluate differences in postoperative radiotherapy dosages, implant failure rates, patient survival rates, and the ability to visualize disease progression via imaging post-operation.
Ash notes that both groups showed similar demographic characteristics, primarily affected by multiple myeloma, with femurs being the most common site of metastatic involvement. The study found no implant failures during the five-year follow-up, but there were some noteworthy instances of periprosthetic fractures in the carbon-fiber group, although these lacked significant clinical correlation due to small data volume.
In terms of survival, around 40% of patients survived two years post-operation, suggesting many were already on a palliative pathway before undergoing surgery. The visualization of disease progression using imaging techniques was emphasized as a challenge, with radiological artifacts from titanium rather than carbon-fiber nails impacting assessments.
In conclusion, while some radiological advantages for carbon-fiber nails were noted, Ash questions whether the small benefit justifies the significant cost, advocating for a focus on patients with a better prognosis who might benefit from enhanced imaging. Recommendations included the need for larger data sets and further research into clinical outcomes compared to theoretical advantages.